You are in: eMedicine Specialties > Dermatology > ENVIRONMENTAL Animal BitesArticle Last Updated: May 25, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Joel Schlessinger, MD, Consulting Staff, Dermatology, Skin Specialists, PC Joel Schlessinger is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, and Phi Beta Kappa Editors: Neil Shear, MD, Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Medical School; Head of Dermatology, Sunnybrook Women's College Health Sciences Center, Canada; Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center; Paul Krusinski, MD, Director of Dermatology, Professor, Department of Internal Medicine, Fletcher Allen Health Care, University of Vermont; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center Author and Editor Disclosure Synonyms and related keywords: dog bites, cat bites, rabies, snakebites, hand bites INTRODUCTIONBackgroundAnimal bites are common, with more than 4.7 million people (almost 2% of the population) in the United States affected each year, according to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. Typically, these are dog or cat bites, with the patient's age most commonly being 7-9 years, but persons of any age can be affected. Typically, the aggressor is a dog, such as a collie, a boxer, or a German shepherd. Other animal bites include bites caused by small animals, such as rabbits, ferrets, monkeys, and farm animals. Certain breeds of animals tend to be more dangerous, and, based on a recent study by the CDC, Allstate Insurance Company comprised a list of 8 dogs they won't insure against bites. On the list are Akitas, boxers, chow chows, Doberman pinschers, pit bulls, American Staffordshire bull terriers, rottweilers, and wolf hybrids.1 In the United States, snakes account for 8000 bites per year. These snakes are typically pit viper types, including rattlesnakes, copperheads, cottonmouth water moccasins, and coral snakes. Many of these snake bites occur after hurricanes and floods (eg, Hurricane Katrina) and may be avoided or mitigated with sensible precautions.2 Interestingly, a recent retrospective study by Bhattacharjee et al3 showed that animal bites increase significantly during a full moon. This study, performed in PathophysiologyThe body site on which dog bites occur varies with age; however, the hand is most frequently involved in cat bites. Snakebites can cause a variety of symptoms, including diarrhea, a burning sensation and pain at the wound site, convulsions, fainting, dizziness, weakness, blurred vision, fever, increased thirst, nausea and vomiting, numbness and tingling, and tachycardia. Dog bites may cause infections by Staphylococcus, Streptococcus, Eikenella, Pasteurella, Proteus, Klebsiella, Haemophilus, Enterobacter, Capnocytophaga (formerly CDC group DF-2), and Bacteroides species. Cat bites may cause infections by Pasteurella, Actinomyces, Propionibacterium, Bacteroides, Fusobacterium, Clostridium, Wolinella, Peptostreptococcus, Staphylococcus, and Streptococcus species. FrequencyUnited StatesThe incidence of dog bites is 4.7 million people per year in the Mortality/MorbidityAnnually, in the United States, 10-20 people receive bites that are fatal. Elderly people are more susceptible to animal bites because their ability to fend off attacks is compromised. Although mortality is rare with most animal bites in the United States, morbidity is common, especially with cat bites infected by Pasteurella species. Dog bites may become infected by Pasteurella species as well. From 1979 to 1996, 304 people in the United States died from dog bites, according to data from the CDC.
SexMales are typically bitten by dogs; usually, young males are most frequently affected. Conversely, women are more frequently bitten by cats than are men. AgeAs a result of their vulnerability and increased possibility of exposure to the animals, individuals who are bitten are usually younger or older persons. CLINICALHistoryUsually, patients with animal bites present to the ED. Occasionally, patients may present to the dermatology office. In either case, inquire about the following:
Physical
CausesUsually, causes of animal bites are related to the possibility of exposure to the animals.
DIFFERENTIALSCellulitis
|
| Drug Name | Amoxicillin and clavulanate (Augmentin) |
|---|---|
| Description | Broad-spectrum antibiotic that can effectively cover infections caused by Staphylococcus and Pasteurella species. Treats bacterial infection resistant to beta-lactam antibiotics. In children >3 mo, base dosing protocol on amoxicillin content because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5). Do not use 250-mg tab until child weighs >40 kg. |
| Adult Dose | 500/125 mg PO tid or 875/125 mg PO bid |
| Pediatric Dose | 10-15 mg/kg PO tid |
| Contraindications | Documented hypersensitivity; history of Augmentin-associated jaundice/hepatic dysfunction |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding; may decrease contraceptive effectiveness; concurrent use of allopurinol and amoxicillin associated with increase in frequency of rash due to amoxicillin; may increase toxicity of methotrexate (penicillins may interfere with renal tubular secretion of methotrexate); high penicillin-to-aminoglycoside ratio (greater than 50:1) for prolonged period may result in chemical inactivation of both compounds |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Administer minimum of 10 d to eliminate organisms and to prevent sequelae (eg, endocarditis, rheumatic fever); following treatment, perform cultures to confirm eradication of streptococci; hepatotoxicity may occur; mononucleosis may increase risk for rash; nausea, vomiting, diarrhea may occur; clavulanic acid may cause a false-positive Coombs test result (must be excluded before further testing or treating for immune-mediated hemolytic process) |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits. Useful for many skin conditions and is the second-line drug for the treatment of infections caused by P multocida. Unfortunately, staphylococcal coverage is poor; therefore, it is currently a poor choice unless infection with Pasteurella species is the primary concern and the patient is allergic to penicillin. |
| Adult Dose | 500 mg PO qid for 10 d |
| Pediatric Dose | <8 years: Not recommended >8 years: Not established |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Occasionally can cause candidal infections in women who are predisposed; photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations during prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Cephalexin (Keflex, Biocef, Keftab) |
|---|---|
| Description | First-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Has bactericidal activity against rapidly growing organisms. Has primary activity against skin flora; used for skin infections or prophylaxis in minor procedures. Although cephalosporins have significant staphylococcal coverage in most populations, coverage of Pasteurella species is not as good as amoxicillin and clavulanate. |
| Adult Dose | 500 mg PO qid for 10 d |
| Pediatric Dose | Mild-to-moderate infection: 25-50 mg/kg/d PO divided q6h; not to exceed 4 g/d depending on type and severity of infection Severe infection: 50-100 mg/kg/d PO divided q6h depending on type and severity of infection |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aminoglycosides increases nephrotoxic potential; cholestyramine may decrease absorption; may increase metformin toxicity; |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in patients with GI disease (particularly colitis); may result in false-positive reaction for urine glucose using copper-reduction method (eg, Clinitest, Benedict solution, Fehling solution); use urine glucose tests based on enzymatic glucose oxidase reactions (eg, Clinistix, or Tes-Tape) in patients receiving cephalexin therapy |
| Drug Name | Cefadroxil (Duricef) |
|---|---|
| Description | First-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. |
| Adult Dose | 1-2 g/d PO divided bid |
| Pediatric Dose | <10 kg: 125 mg PO bid for 10 d 10-30 kg: 250 mg PO bid for 10 d >30 kg: 30 mg/kg/d PO divided bid; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity; history of gastrointestinal disease, particularly colitis |
| Interactions | Probenecid may decrease clearance; aminoglycosides and furosemide may decrease nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe renal insufficiency; high doses may cause CNS toxicity; prolonged use may result in superinfection |
| Drug Name | Moxifloxacin (Avelox, Vigamox) |
|---|---|
| Description | Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription. |
| Adult Dose | 400 mg PO/IV qd |
| Pediatric Dose | Not recommended |
| Contraindications | Documented hypersensitivity; known Q-T prolongation, concurrent administration of drugs that cause Q-T prolongation |
| Interactions | Antacids and electrolyte supplements reduce absorption; loop diuretics, probenecid, and cimetidine increase serum levels; NSAIDs enhance CNS stimulating effect May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); ferrous sulfate decreases bioavailability (administer moxifloxacin 4 h prior or 8 h following ferrous sulfate); coadministration with drugs that prolong QTc interval (quinidine, procainamide, amiodarone, sotalol, erythromycin, TCAs) increases risk of life-threatening arrhythmia; coadministration with corticosteroids may increase risk of tendon rupture; didanosine, sucralfate, and aluminum- or magnesium-containing antacids may reduce absorption of quinolones |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy; fluoroquinolones have induced seizures in persons with CNS disorders and have caused tendinitis or tendon rupture; peripheral neuropathy may occur; prolonged QT interval and torsades de pointes reported; may cause traumatic or nontraumatic tendon rupture; may predispose to seizures or lower seizure threshold; may result in false-positive urine opiate screening |
| Drug Name | Erythromycin (Eryc, E.E.S.) |
|---|---|
| Description | Recommended dosing schedule of erythromycin may result in GI upset, causing one to prescribe an alternative macrolide or change to tid dosing. Covers most potential etiologic agents, including Mycoplasma species. Erythromycin is less active against H influenzae. Although 10 d seems to be a standard course of treatment, treating until the patient has been afebrile for 3-5 d seems a more rational approach. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose. Has the added advantage of being a good anti-inflammatory agent by inhibiting migration of polymorphonuclear leukocytes. |
| Adult Dose | 250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) PO q6h, or 500 mg q12h (1 h ac or 2 h pc) Alternatively, 333 mg PO q8h; increase to 4 g/d depending on severity of infection |
| Pediatric Dose | 20-50 mg/kg/d PO divided qid; not to exceed 500 mg/dose |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin, increases risk of rhabdomyolysis; decreases metabolism of repaglinide, thus increasing serum levels and effects |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI side effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
These agents are used with rabies vaccine in individuals previously unvaccinated to provide maximum coverage before immune response to the vaccine occurs.
| Drug Name | Rabies immune globulin (Hyperab, Imogam) |
|---|---|
| Description | Provides passive protection to individuals exposed to rabies virus. Administer approximately half the dose into and around the bite wound as much as possible (given anatomical constraints), and the rest is given intramuscularly at a site remote from the vaccine administration area in the gluteal or deltoid muscle. |
| Adult Dose | 20 U/kg IM once after exposure, preferably with first dose of vaccine |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; isolated immunoglobulin A deficiency |
| Interactions | Through antigen-antibody antagonism, may diminish antibody response to MMR vaccine; administer live virus vaccines 14-30 d before or 6-12 wk after immune globulin administration; antibody response to rabies vaccine may be delayed if administered simultaneously with rabies immune globulin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in thrombocytopenia or bleeding disorders; to prevent interference with maximum active immunity from rabies vaccine, not for administration in repeated doses once rabies vaccine treatment initiated |
These agents are used for active immunization against rabies.
| Drug Name | Rabies virus vaccine (RabAvert, HDCV, Imovax) |
|---|---|
| Description | Inactivated forms of virus that promote immunity by inducing an active immune response. Imovax rabies vaccine ID is for preexposure use only via the intradermal route. Administer ID doses into the deltoid area for postexposure vaccination of adults and older children (for younger children, use the outer aspect of the thigh). Never administer in gluteal area. |
| Adult Dose | Preexposure immunization: 1 mL Imovax Rabies Vaccine IM or 0.1 mL Imovax Rabies ID on days 0, 7, and 21-28, then q2-5y depending on antibody titers Postexposure prophylaxis (patients previously unvaccinated): Administer RIG (20 IU/kg) as soon as possible after exposure and a total of 5 IM doses (do not inject ID) each 1 mL on days 0, 3, 7, 14, and 28 Patients previously immunized: 1 mL IM/ID on days 0 and 3; do not administer RIG |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | High-dose corticosteroids or other immunosuppressants (eg, cyclosporine) and radiation therapy may inhibit immunization, causing patients to remain susceptible despite vaccination; avoid use of immunosuppressants during postexposure therapy; persons receiving immunosuppressive therapy should receive RIG IM (3 doses/mL each) |
| Pregnancy | C - Safety for use during pregnancy has not been established |
| Precautions | Inject Imovax Rabies Vaccine only in deltoid area because vaccination may fail if injected into gluteal area; to prevent failure with Imovax Rabies ID, inject ID and not IM; use IM route for Imovax Rabies Vaccine; caution in documented hypersensitivity (may pretreat with antihistamines); epinephrine injection (1:1000), volume replacement, oxygen, and corticosteroids must be available immediately to treat anaphylactic reactions that may occur; carefully consider patient's risk of developing rabies before discontinuing immunization; adverse effects with neural tissue vaccine include anaphylaxis, encephalitis, Guillain-Barré syndrome, meningitis, multiple sclerosis, myelitis, transient paralysis, and retrobulbar neuritis |
These agents are used to neutralize toxins from snakebites. The physician must be prepared to support the victim's cardiovascular and respiratory systems.
| Drug Name | Crotalidae polyvalent immune fab-ovine (CroFab) |
|---|---|
| Description | A purified preparation of immunoglobulin fragment obtained from sheep. Rash, urticaria, and pruritus were seen in approximately 33% of patients tested. Although anaphylaxis was not reported in the trials, 1/7th of the patients did develop a serum sickness–like reaction (though this was in the early tests prior to complete purification of the lot). |
| Adult Dose | Should be given within 6 h of initial bite; 4-6 vials IV over 60 min; an additional 4-6 vials may be given 1 h later if status is not improving and/or coagulation studies are worsening; an additional 4-6 vials may be given another 1 h later if signs are again not improved Maintenance is 2 vials q6h 3 times Other information available at 87SERPDRUG (877-377-3784) |
| Pediatric Dose | Administer as in adults |
| Contraindications | Prior hypersensitivity to polyvalent crotalid antivenin ovine Fab or any other sheep-derived product; known sensitivity to papain or papaya |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | History of allergic responses or untoward effects after the administration of the standard equine vaccine; a known hypersensitivity to the pineapple-derived enzyme bromelain; a severe venom poisoning (due to lacking clinical data); renal hepatic insufficiency (no pharmokinetic data); copperhead envenomation (because of minimal clinical data); recurrence of symptoms (coagulopathy) may occur after the initial infusion; pregnancy; sensitivity to compounds containing mercury (contains ethyl mercury from thimerosal) thimerosal sensitivity |
Article Last Updated: May 25, 2007